Rtw Investments 13F: Adds $12M to Fulgent Genetics (FLGT) Stake

RTW Investments has significantly increased its stake in Fulgent Genetics, Inc. (NasdaqGM: FLGT) according to the latest Form 13F filing with the SEC dated May 15, 2026. The firm added 583,973 shares, bringing its total holdings to 1,289,000 shares. This move represents an 82.8% increase, with the stake valued at approximately $24.08 million as of the reporting period.

What Changed in RTW Investments' Fulgent Genetics Position

RTW Investments boosted its investment in Fulgent Genetics by adding 583,973 shares to its portfolio, raising its total holdings to 1,289,000 shares. This increase reflects an 82.8% jump from its previous count of 705,027 shares. The value of this position was reported at about $24.08 million.

Other Institutional Activity in Fulgent Genetics

Several other institutional investors have also adjusted their positions in Fulgent Genetics. BlackRock, Inc. slightly reduced its holdings by 187,715 shares, ending with 2,774,519 shares valued at approximately $44.11 million. Acadian Asset Management LLC added 48,061 shares, bringing its total to 1,233,951 shares worth about $19.60 million. Vanguard Capital Management LLC made a significant addition by acquiring 880,150 shares, matching its total share count, valued at $13.99 million. Dimensional Fund Advisors LP, however, reduced its position by 217,348 shares, leaving it with 671,664 shares valued at $10.68 million.

Fulgent Genetics, Inc. Stock Down 5.4%

Shares of Fulgent Genetics traded near $18.68 recently. The company has a market cap of approximately $530.5 million. It currently does not have a meaningful P/E ratio as it is not profitable, with a forward P/E of -12.23. The stock has a 52-week low of $13.46 and a high of $31.04. Its 50-day moving average is $16.54, while the 200-day moving average is $21.79. The company's current ratio is 5.32, with a quick ratio of 3.91 and a debt-to-equity ratio of 0.97.

Recent Earnings

Fulgent Genetics reported revenue of $320.3 million, with a revenue growth decline of 3.2%. The company recorded a net margin of -23.04% and a return on equity of -6.92%. Its next earnings report is expected on July 31, 2026.

Insider Buying and Selling at Fulgent Genetics, Inc.

Insider activity at Fulgent Genetics included several sales. On June 2, 2026, Chief Scientific Officer Gao Hanlin and President and COO Xie Jian sold 1,688 and 2,146 shares respectively, at an average price of $17.89. On June 1, CEO Ming Hsieh and CFO Paul Kim sold 4,392 and 2,087 shares respectively, at $18.09 per share.

Analysts Set New Price Targets

On May 5, 2026, Piper Sandler reiterated its hold rating for Fulgent Genetics with a price target of $15. The consensus among analysts suggests a target mean price of $18.50, with two analysts providing opinions.

About Fulgent Genetics

Fulgent Genetics, Inc. is a healthcare company based in El Monte, California, specializing in diagnostic and therapeutic development solutions. Founded in 2011, it offers a range of diagnostic tests and therapeutic development services, focusing on areas like molecular diagnostics, genetic testing, and oncology. The company is led by CEO Ming Hsieh and employs about 1,315 people.

Bottom Line

RTW Investments' significant increase in its Fulgent Genetics position highlights its confidence in the company's potential. Investors often track such moves to gauge institutional sentiment. However, it's important to remember that 13F filings reflect past holdings and may not indicate current positions.